Acutus Medical (AFIB) Q4 2024 earnings summary

Executive summary

• 2024 revenue from continuing operations reached $20.2 million, up 181% year-over-year from $7.2 million.

• Operating loss for continuing operations narrowed to $0.1 million from $11.7 million last year.

• Net loss from continuing operations was $4.6 million, with net loss per share at $0.16, compared to $11.9 million and $0.40 per share last year.

• Loss on discontinued operations was $5.0 million, a significant improvement from $69.7 million last year.

• Company realigned focus to left-heart access products and exited electrophysiology mapping and ablation businesses.

Financial highlights

• Gross margin for continuing operations improved to 5% from negative 44% year-over-year, driven by higher production volumes and reduced overhead.

• Operating expenses for continuing operations dropped to $1.1 million from $8.6 million, reflecting reduced discretionary spend.

• Cash, cash equivalents, marketable securities, and restricted cash totaled $14.0 million as of December 31, 2024.

• Gain on sale of business was $10.8 million, up 19% year-over-year.

Outlook and guidance

• No further financial guidance will be provided due to the business realignment and exit from certain business lines.